Document is current
Any future updates will be listed below
-
Authors
Gharbi-Meliani, Amin https://orcid.org/0000-0001-7788-3321
Husson, François https://orcid.org/0000-0002-7271-8877
Vandendriessche, Henri https://orcid.org/0000-0001-9319-0031
Bayen, Eleonore https://orcid.org/0000-0002-0286-5521
Yaffe, Kristine https://orcid.org/0000-0003-0919-3825
Bachoud-Lévi, Anne-Catherine https://orcid.org/0000-0003-3000-2210
Cleret de Langavant, Laurent https://orcid.org/0000-0001-6551-4641
-
Funding
Funding for this research was provided by:
French Institute for Public Health Research
French National Institute for Health and Medical Research
NeurATRIS (ANR-11-INBS-0011, ANR-11-INBS-0011, ANR-11-INBS-0011)
Front-Cog University Research School (ANR-17-EUR-0017, ANR-17-EUR-0017, ANR-17-EUR-0017)
- License Information
-
More Information
Article History
Received: 23 June 2023
Accepted: 21 November 2023
First Online: 29 November 2023
Declarations
:
: All participants provided informed consent and both studies obtained ethical approvals from local research committees. SHARE was approved by committees at the University of Mannheim and the Max Planck society. ELSA was first approved by the London Multicenter Research Ethics Committee (MREC/01/2/91). Information about the ethical committees of the following waves is available at .
: Not applicable.
: E.B. is an advisory board member of SafelyYou. E.B. has vested stock options in SafelyYou stock. K.F. is a participant on a data safety monitoring board Eli Lilly and NIH-sponsored trials. K.F. is a board member of Alector. A.C.B.L. has received academic grants from the French National Research Agency (ANR-17-EURE-0017) and NeurATRIS (ANR-11-INBS-0011). A.C.B.L. has received fees for consultancy work from Roche. All other authors declare no competing interests.
